Procter & Gamble
Restructuring program will not disrupt prescription drug developments, company CEO Durk Jager says. P&G is on track for approvals of the anti-arrhythmia drug Stedicor (azimilide) within 12 months and an osteoporosis supplement for Actonel (risedronate) within nine months. P&G plans to establish 11 global business units to improve innovation and speed of commercialization. Restructuring will include lay offs of 15,000 employees worldwide, approximately 13.6% of P&G's 110,000-person workforce
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth